Dr. Reddy's Laboratories Limited (DRREDDY) — Corporate Action | 9 May 2025(2 announcements)

Dr. Reddy's Laboratories reported a 16% YoY revenue increase to ₹53.7 billion in FY25, driven by 23% growth in Global Generics and 145% growth in Europe, with gross margin at 55.6% and net profit up 22% to ₹5.9 billion in Q4FY25. The Board recommended an ₹8 final dividend per share, reappointed G V Prasad for a 5-year term pending shareholder approval, and convened the 41st AGM on July 24, 2025. A 1:5 stock split was approved, converting Rs 5 face value shares into five Rs 1 shares, effective October 28, 2024, with post-split equity shares at 834,455,365. The company also recorded a ₹1,551 million foreign exchange gain reclassification and a ₹473 million deferred tax asset write-off.

Dr. Reddy's Laboratories reported a 20% YoY revenue jump to ₹53.7 billion in FY25, driven by 23% growth in Global Generics and 145% surge in Europe, while gross margin slipped 300 bps to 55.6% amid foreign exchange gains and deferred tax write-offs. The Board recommended an ₹8 final dividend per share, reappointed G V Prasad for 5 years pending shareholder approval, and finalized a 1:5 stock split effective October 2024, adjusting all financials post-split. The AGM is set for July 24, 2025, with record date for dividend eligibility on July 10, 2025.